Wintermute Biomedical is an antimicrobials-focused pharmaceutical company located in Melbourne, Australia and Missoula, Montana. We have developed a novel platform for harnessing the antimicrobial activity of fatty acids, with a focus on developing a next-generation treatment for Shingles. Our lead product Solexan™ is now in clinical trials. Our vision is to make Solexan™ available for the millions of people who fall victim to Shingles each year.